中国肺癌杂志2012，Vol.15Issue(1)：6-10,5.DOI:10.3779/j.issn.1009-3419.2012.01.02
贝伐珠单抗联合紫杉醇/卡铂治疗晚期非小细胞肺癌25例分析
Evaluation of Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Chinese Patients withAdvanced Non-small Cell Lung Cancer
赵肖 1王孟昭 1张力 1李龙芸 1钟巍1
作者信息
- 1. 100730北京,中国医学科学院北京协和医学院,北京协和医院呼吸内科
- 折叠
摘要
Abstract
Background and objective The current study reported the result of bevacizumab treatment administered to 25 Chinese patients with advanced non-small cell lung cancer (NSCLC) who were treated at the Peking Union Medical College Hospital as a part of the SAiL (MO19390) trial. This trial is an open, international multicenter, single-arm clinical study that assesses the safety and efficacy of first-line bevacizumab-based therapy in advanced NSCLC. Methods Twenty-five Chinese patients with advanced non-squamous NSCLC received bevacizumab (IS mg/kg) combined with chemotherapy (carboplatin plus paditaxel) treatment from August 2007 to February 2008. Adverse effects (Aes), objective response rate (ORR), median time to progression (TTP), and overall survival (OS) were measured. Results Aes were generally mild and reversible. The most frequent Aes were alopecia, peripheral neuropathy, rash, proteinuria, nausea/vomitting, fatigue, myalgia, bleeding, and hypertension. The partial remission and stable disease rates were 68% and 28%, respectively. The median TTP and OS of all patients were 11.2 and 19.3 months, respectively. Conclusion Bevacizumab combined with carboplatin-based chemotherapy may be well tolerated and beneficial for Chinese patients with non-squamous NSCLC.关键词
肺肿瘤/贝伐珠单抗/不良反应/治疗Key words
Lung neoplasms/ Bevacizumab/ Adverse effect/ Therapy分类
医药卫生引用本文复制引用
赵肖,王孟昭,张力,李龙芸,钟巍..贝伐珠单抗联合紫杉醇/卡铂治疗晚期非小细胞肺癌25例分析[J].中国肺癌杂志,2012,15(1):6-10,5.
